Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer

This phase I study (RAD1901-005; NCT02338349) evaluated elacestrant, an investigational oral selective estrogen receptor degrader (SERD), in heavily pretreated women with estrogen receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer, including those with estr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Bardia, Aditya, Kaklamani, Virginia, Wilks, Sharon, Weise, Amy, Richards, Donald, Harb, Wael, Osborne, Cynthia, Wesolowski, Robert, Karuturi, Meghan, Conkling, Paul, Bagley, Rebecca G., Wang, Yamei, Conlan, Maureen G., Kabos, Peter
Formato: Artigo
Idioma:Inglês
Publicado em: Wolters Kluwer Health 2021
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8078341/
https://ncbi.nlm.nih.gov/pubmed/33513026
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.02272
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados